Linked Life Data

2653494

Source:http://linkedlifedata.com/resource/pubmed/id/2653494

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1989-6-12
pubmed:abstractText
Lymphokine activated killer (LAK) cells are being considered as a new and promising form of immunotherapy in the management of patients with solid tumours. Few informations are instead available on these cytotoxic effectors in haematological neoplasias. Here we shall discuss the possible role of LAK cells in human leukaemias. Evidence will be provided for a rationale in the clinical exploitment of Interleukin 2 (IL2)/LAK cells in the treatment of acute leukaemia patients, whilst the implication of these cytotoxic populations appears more uncertain in chronic lymphoproliferative disorders.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0268-3369
pubmed:author
pubmed:issnType
Print
pubmed:volume
4 Suppl 1
pubmed:owner
NLM
pubmed:authorsComplete
N
pubmed:pagination
153-5
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed:year
1989
pubmed:articleTitle
Lymphokine activated killer (LAK) activity in lymphoproliferative disorders.
pubmed:affiliation
Dipartimento di Scienze Biomediche e Oncologia Umana, University of Torino, Italy.
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't